The RasGAP Gene, RASAL2, Is a Tumor and Metastasis Suppressor

Cancer Cell

Volumn 24, Issue 3, 2013, Pages 365-378

  McLaughlin, Sara Koenig ^a,b   Olsen, Sarah Naomi ^a,b   Dake, Benjamin ^c,d   De Raedt, Thomas ^a,b,g   Lim, Elgene ^a,b,e   Bronson, Roderick Terry ^b   Beroukhim, Rameen ^a,b,e,f   Polyak, Kornelia ^a,b,e   Brown, Myles ^a,b,e   Kuperwasser, Charlotte ^c,d   Cichowski, Karen ^a,b,g  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d TUFTS MEDICAL CENTER   (United States)

^e DANA FARBER CANCER INSTITUTE   (United States)

^f HARVARD UNIVERSITY   (United States)

^g DANA FARBER HARVARD CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ANGIOMA; ANGIOSARCOMA; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BILE DUCT CARCINOMA; BREAST ADENOCARCINOMA; CANCER INHIBITION; CANCER RECURRENCE; COLON ADENOMA; CONTROLLED STUDY; EMBRYO; EMBRYONIC STEM CELL; FEMALE; GASTROINTESTINAL POLYPOSIS; GENE INACTIVATION; GENE LOSS; HISTIOCYTIC SARCOMA; HUMAN; HUMAN CELL; INVASIVE CARCINOMA; LEIOMYOSARCOMA; LIVER CELL CARCINOMA; LIVER METASTASIS; LUNG ADENOCARCINOMA; LUNG METASTASIS; LYMPHOMA; METASTASIS INHIBITION; MOUSE; MOUSE MUTANT; MOUTH CARCINOMA; NONHUMAN; ONCOGENE RAS; OSTEOMA; OSTEOSARCOMA; PAPILLOMA; PHEOCHROMOCYTOMA; PRIMARY TUMOR; PRIORITY JOURNAL; RASAL2 GENE; RHABDOMYOSARCOMA; SQUAMOUS CELL CARCINOMA; STOMACH TUMOR; TUMOR SUPPRESSOR GENE; TUMOR XENOGRAFT; WILD TYPE; XENOGRAFT;

EID: 84883618312     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccr.2013.08.004     Document Type: Article

References (43)

1. Bamford S., Dawson E., Forbes S., Clements J., Pettett R., Dogan A., Flanagan A., Teague J., Futreal P.A., Stratton M.R., Wooster R. The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website. Br. J. Cancer 2004, 91:355-358.
2. Bernards A. GAPs galore! A survey of putative Ras superfamily GTPase activating proteins in man and Drosophila. Biochim. Biophys. Acta 2003, 1603:47-82.
3. Comprehensive molecular portraits of human breast tumours. Nature 2012, 490:61-70. Cancer Genome Atlas Network.
4. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008, 455:1061-1068. Cancer Genome Atlas Research Network.
5. Cawthon R.M., Weiss R., Xu G.F., Viskochil D., Culver M., Stevens J., Robertson M., Dunn D., Gesteland R., O'Connell P., et al. A major segment of the neurofibromatosis type 1 gene: cDNA sequence, genomic structure, and point mutations. Cell 1990, 62:193-201.
6. Ding L., Getz G., Wheeler D.A., Mardis E.R., McLellan M.D., Cibulskis K., Sougnez C., Greulich H., Muzny D.M., Morgan M.B., et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008, 455:1069-1075.
7. Donehower L.A., Harvey M., Slagle B.L., McArthur M.J., Montgomery C.A., Butel J.S., Bradley A. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 1992, 356:215-221.
8. Dote H., Toyooka S., Tsukuda K., Yano M., Ouchida M., Doihara H., Suzuki M., Chen H., Hsieh J.-T., Gazdar A.F., Shimizu N. Aberrant promoter methylation in human DAB2 interactive protein (hDAB2IP) gene in breast cancer. Clin. Cancer Res. 2004, 10:2082-2089.
9. Downward J. Targeting RAS signalling pathways in cancer therapy. Nat. Rev. Cancer 2003, 3:11-22.
10. Gewinner C., Wang Z.C., Richardson A., Teruya-Feldstein J., Etemadmoghadam D., Bowtell D., Barretina J., Lin W.M., Rameh L., Salmena L., et al. Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling. Cancer Cell 2009, 16:115-125.
11. Györffy B., Lanczky A., Eklund A.C., Denkert C., Budczies J., Li Q., Szallasi Z. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res. Treat. 2010, 123:725-731.
12. Guy C.T., Webster M.A., Schaller M., Parsons T.J., Cardiff R.D., Muller W.J. Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc. Natl. Acad. Sci. USA 1992, 89:10578-10582.
13. Herschkowitz J.I., Simin K., Weigman V.J., Mikaelian I., Usary J., Hu Z., Rasmussen K.E., Jones L.P., Assefnia S., Chandrasekharan S., et al. Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol. 2007, 8:R76.
14. Hollestelle A., Elstrodt F., Nagel J.H.A., Kallemeijn W.W., Schutte M. Phosphatidylinositol-3-OH kinase or RAS pathway mutations in human breast cancer cell lines. Mol. Cancer Res. 2007, 5:195-201.
15. Hölzel M., Huang S., Koster J., Ora I., Lakeman A., Caron H., Nijkamp W., Xie J., Callens T., Asgharzadeh S., et al. NF1 is a tumor suppressor in neuroblastoma that determines retinoic acid response and disease outcome. Cell 2010, 142:218-229.
16. Hu Z., Fan C., Oh D.S., Marron J.S., He X., Qaqish B.F., Livasy C., Carey L.A., Reynolds E., Dressler L., et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 2006, 7:96.
17. Hu M., Yao J., Carroll D.K., Weremowicz S., Chen H., Carrasco D., Richardson A., Violette S., Nikolskaya T., Nikolsky Y., et al. Regulation of insitu to invasive breast carcinoma transition. Cancer Cell 2008, 13:394-406.
18. Jacks T., Remington L., Williams B.O., Schmitt E.M., Halachmi S., Bronson R.T., Weinberg R.A. Tumor spectrum analysis in p53-mutant mice. Curr. Biol. 1994, 4:1-7.
19. Jézéquel P., Campone M., Gouraud W., Guérin-Charbonnel C., Leux C., Ricolleau G., Campion L. bc-GenExMiner: an easy-to-use online platform for gene prognostic analyses in breast cancer. Breast Cancer Res. Treat. 2012, 131:765-775.
20. Johannessen C.M., Reczek E.E., James M.F., Brems H., Legius E., Cichowski K. The NF1 tumor suppressor critically regulates TSC2 and mTOR. Proc. Natl. Acad. Sci. USA 2005, 102:8573-8578.
21. Kamangar F., Dores G.M., Anderson W.F. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J.Clin. Oncol. 2006, 24:2137-2150.
22. Karnoub A.E., Weinberg R.A. Ras oncogenes: split personalities. Nat. Rev. Mol. Cell Biol. 2008, 9:517-531.
23. Kim I.S., Baek S.H. Mouse models for breast cancer metastasis. Biochem. Biophys. Res. Commun. 2010, 394:443-447.
24. Krauthammer M., Kong Y., Ha B.H., Evans P., Bacchiocchi A., McCusker J.P., Cheng E., Davis M.J., Goh G., Choi M., et al. Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat. Genet. 2012, 44:1006-1014.
25. Lim E., Vaillant F., Wu D., Forrest N.C., Pal B., Hart A.H., Asselin-Labat M.-L., Gyorki D.E., Ward T., Partanen A., et al. Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat. Med. 2009, 15:907-913. kConFab.
26. Maertens O., Johnson B., Hollstein P., Frederick D.T., Cooper Z.A., Messaien L., Bronson R.T., McMahon M., Granter S., Flaherty K.T., et al. Elucidating distinct roles for NF1 in melanomagenesis. Cancer Discov. 2012, 3:338-349.
27. McGillicuddy L.T., Fromm J.A., Hollstein P.E., Kubek S., Beroukhim R., De Raedt T., Johnson B.W., Williams S.M.G., Nghiemphu P., Liau L.M., et al. Proteasomal and genetic inactivation of the NF1 tumor suppressor in gliomagenesis. Cancer Cell 2009, 16:44-54.
28. Miller F.R., Santner S.J., Tait L., Dawson P.J. MCF10DCIS.com xenograft model of human comedo ductal carcinoma insitu. J.Natl. Cancer Inst. 2000, 92:1185-1186.
29. Min J., Zaslavsky A., Fedele G., McLaughlin S.K., Reczek E.E., De Raedt T., Guney I., Strochlic D.E., Macconaill L.E., Beroukhim R., et al. An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-kappaB. Nat. Med. 2010, 16:286-294.
30. Mueller H., Flury N., Eppenberger-Castori S., Kueng W., David F., Eppenberger U. Potential prognostic value of mitogen-activated protein kinase activity for disease-free survival of primary breast cancer patients. Int. J. Cancer 2000, 89:384-388.
31. Mueller C., Liotta L.A., Espina V. Reverse phase protein microarrays advance to use in clinical trials. Mol. Oncol. 2010, 4:461-481.
32. Parsons D.W., Jones S., Zhang X., Lin J.C.-H., Leary R.J., Angenendt P., Mankoo P., Carter H., Siu I.-M., Gallia G.L., et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008, 321:1807-1812.
33. Perou C.M., Sørlie T., Eisen M.B., van de Rijn M., Jeffrey S.S., Rees C.A., Pollack J.R., Ross D.T., Johnsen H., Akslen L.A., et al. Molecular portraits of human breast tumours. Nature 2000, 406:747-752.
34. Pylayeva-Gupta Y., Grabocka E., Bar-Sagi D. RAS oncogenes: weaving a tumorigenic web. Nat. Rev. Cancer 2011, 11:761-774.
35. Shah S.P., Roth A., Goya R., Oloumi A., Ha G., Zhao Y., Turashvili G., Ding J., Tse K., Haffari G., et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 2012, 486:395-399.
36. Sivaraman V.S., Wang H., Nuovo G.J., Malbon C.C. Hyperexpression of mitogen-activated protein kinase in human breast cancer. J.Clin. Invest. 1997, 99:1478-1483.
37. Sjöblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., Mandelker D., Leary R.J., Ptak J., Silliman N., et al. The consensus coding sequences of human breast and colorectal cancers. Science 2006, 314:268-274.
38. Song M.S., Salmena L., Pandolfi P.P. The functions and regulation of the PTEN tumour suppressor. Nat. Rev. Mol. Cell Biol. 2012, 13:283-296.
39. Sørlie T., Perou C.M., Tibshirani R., Aas T., Geisler S., Johnsen H., Hastie T., Eisen M.B., van de Rijn M., Jeffrey S.S., et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. USA 2001, 98:10869-10874.
40. Thomas G.V., Horvath S., Smith B.L., Crosby K., Lebel L.A., Schrage M., Said J., De Kernion J., Reiter R.E., Sawyers C.L. Antibody-based profiling of the phosphoinositide 3-kinase pathway in clinical prostate cancer. Clin. Cancer Res. 2004, 10:8351-8356.
41. von Lintig F.C., Dreilinger A.D., Varki N.M., Wallace A.M., Casteel D.E., Boss G.R. Ras activation in human breast cancer. Breast Cancer Res. Treat. 2000, 62:51-62.
42. Vousden K.H., Lane D.P. p53 in health and disease. Nat. Rev. Mol. Cell Biol. 2007, 8:275-283.
43. Weigelt B., Peterse J.L., van 't Veer L.J. Breast cancer metastasis: markers and models. Nat. Rev. Cancer 2005, 5:591-602.